Low Evidence
Research Overview
IGF-1 LR3 Research for Diabetes/Glucose Metabolism
An evidence-based overview of research examining IGF-1 LR3 in the context of diabetes/glucose metabolism. This page synthesizes findings from peer-reviewed literature.
Research Summary
IGF-1 can improve insulin sensitivity and glucose uptake via GLUT4 translocation. However, the hypoglycemic effects are a significant safety concern. Native IGF-1 (mecasermin) is approved for IGF-1 deficiency but not for diabetes.
Referenced Studies
Click any PMID to view the full study on PubMed.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. IGF-1 LR3 has not received regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.